Acquisition Opportunity Tentamus Group acquired CardioMed Device Consultants in October 2024, signaling a strategic consolidation in medical device regulatory consulting and testing. This creates potential cross-sell opportunities for Tentamus’ broader services to CardioMed’s clients and vice versa, especially for customers seeking end-to-end regulatory, testing, and compliance support.

Regulatory Expertise Strong regulatory, engineering, and clinical experience with FDA ties positions CardioMed as a trusted partner for medical device makers aiming to navigate complex approval processes quickly. Prospective clients include early-stage startups and mid-sized manufacturers seeking accelerated regulatory pathways.

Market Positioning Small to mid-sized device manufacturers (11-50 employees) form CardioMed’s core addressable market, a segment often seeking specialized external support. There is potential to expand services to larger manufacturers through added capabilities or partnerships, leveraging Tentamus’ vast network.

Technology & Accessibility Existing tech stack based on WordPress, Google Workspace, and standard web tools suggests room to modernize client-facing offerings and self-service resources. Investment in digital marketing and client portals could attract more inquiries from growth-stage companies seeking regulatory clarity and project management transparency.

Financial Growth Signals Reported revenue of $1M-$10M indicates a viable, revenue-generating practice with room to scale through broader service lines, geographic expansion, or integration with Tentamus’ global capabilities. Target messaging can emphasize scalable regulatory projects and long-term retainer opportunities.